Knightscope, Inc. Class A KSCP 深 滬
等待開盤 04-24 09:30:00 美东时间
3.15
-0.170
-5.12%
華盛通- 最 高3.30
- 今 開3.30
- 成交量 50.98万股
- 最 低 3.08
- 昨 收 3.32
- 總市值 5129.12万
- 52周最高 10.14
- 市盈率 靜 --
- 換手率 3.13%
- 52周最低 2.92
- 委 比 -60.00%
- 總股本 1628.29万
- 歷史最高 1375.00
- 量 比 1.03
- 振 幅 6.63%
- 歷史最低 2.45
- 每 手 1
- 風險率 1.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
Microsoft To $500? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and upgrades/downgrades on our analyst ratings page.
04-15 21:00
Ascendiant Capital Maintains Buy on Knightscope, Raises Price Target to $26
Ascendiant Capital analyst Edward Woo maintains Knightscope (NASDAQ:KSCP) with a Buy and raises the price target from $25 to $26.
04-15 18:09
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
HC Wainwright & Co. Reiterates Buy on Knightscope, Maintains $12 Price Target
HC Wainwright & Co. analyst Scott Buck reiterates Knightscope (NASDAQ:KSCP) with a Buy and maintains $12 price target.
03-31 18:45
Knightscope Q4 EPS $(0.92) Misses $(0.78) Estimate, Sales $2.538M Miss $2.873M Estimate
Knightscope (NASDAQ:KSCP) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.78) by 17.5 percent. This is a 17.95 percent decrease over losses of $(0.78) per share from the
03-30 21:20
Knightscope Hits $2M In New Sales, Client Renewals
Knightscope, Inc. (NASDAQ: KSCP), a security technology company building the Nation's First Autonomous Security Force, today announced that it has surpassed another $2 million milestone in new sales and client renewals.
02-26 23:35
美股大行评级 | 安森美半导体获多家大行调目标价；BD医疗、Dynatrace、Monday、Regenxbio遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持内克塔治疗"买入"评级，目标价从135美元升至165美元；BTIG：维持内克塔治疗"买入"评级，目标价从118美元升至151美元
02-11 11:02
HC Wainwright & Co. Reiterates Buy on Knightscope, Maintains $12 Price Target
HC Wainwright & Co. analyst Scott Buck reiterates Knightscope (NASDAQ:KSCP) with a Buy and maintains $12 price target.
02-10 19:43
Knightscope Retains Lake Street Capital Markets As Its Buy-Side Financial Adviser
Knightscope, Inc. (NASDAQ: KSCP), a security technology company building the Nation's first Autonomous Security Force, today announced that it has retained Lake Street Capital Markets, a full-service investment bank, as
02-05 22:11
